[NADH的治疗潜力:在神经退行性疾病中以线粒体功能障碍为特征]
Ziyi Chen1, Hongyang Wang1, Qiuju Wang1
1Department of Audiology and Vestibular Medicine，Institute of Otolaryngology，Senior Department of Otolaryngology Head and Neck Surgery，the Sixth Medical Center of Chinese PLA General Hospital，National Clinical Research Center for Otolaryngologic Diseases，Beijing，100048，China.
概括
尼古丁胺胺氨基二核酸 (NADH) 对细胞能量和线粒体功能至关重要. 提高NADH水平可能为神经退行性疾病 (如听力神经病变) 提供治疗策略.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 线粒体生物学 线粒体生物学
背景情况:
- 尼古丁胺胺氨基二核酸 (NADH) 是氧化还原反应中的关键辅酶,对于能量恒温是必不可少的.
- 降低的NAD+/NADH水平与线粒体功能障碍有关,这是帕金森病和阿尔茨海默病等神经退行性疾病的关键因素.
- 听力神经病变 (AN) 作为神经退行性疾病的临床生物标志物,其中线粒体功能障碍与遗传突变有关 (例如,OPA1,AIFM1).
研究的目的:
- 审查NAD+/NADH代谢途径和生物功能.
- 探索NADH在治疗听力神经病变中的治疗潜力和机制.
- 要突出线粒体功能障碍,神经退行和听觉神经病变之间的联系.
主要方法:
- 文献综述侧重于NAD+/NADH代谢.
- 分析线粒体功能障碍在神经退行性疾病中的作用.
- 检查涉及NAD+前体和NADH的治疗策略.
主要成果:
- NAD+/NADH水平对于能量恒温和线粒体功能至关重要.
- 线粒体功能障碍与神经退行性疾病和听力神经病变有关.
- NAD+前体显示出增强DNA修复和线粒体功能的潜力.
结论:
- 恢复NAD+/NADH平衡是神经退行性疾病的潜在治疗途径.
- 基于NADH的疗法可以减轻线粒体功能障碍和相关的神经系统缺陷.
- 对NADH的机制进行进一步的研究是有必要的,以开发有效的治疗AN.
相关概念视频
01:46Electron Transport Chain: Complex I and II
13.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.4K
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:37Mitochondria
12.6K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
12.6K
01:45Mitochondrial Membranes
10.4K
A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
10.4K
01:29Role of Reduced Coenzymes NADH and FADH₂
11.6K
The energy released from the breakdown of the chemical bonds within nutrients can be stored either through the reduction of electron carriers or in the bonds of adenosine triphosphate (ATP). In living systems, a small class of compounds functions as mobile electron carriers, molecules that bind to and shuttle high-energy electrons between compounds in pathways. The principal electron carriers that will be considered originate from the B vitamin group and are derivatives of nucleotides; they are...
11.6K
01:15Parkinson's Disease: Overview
547
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
547